Willsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, et al
Any decision to incorporate peptide-based therapies is made collaboratively between physician and patient, with a focus on safety, transparency, and evidence-informed care
The depth of medical evaluation in telehealth models is inherently limited
difficulty breathing or swallowing) Changes in vision Signs of kidney problems (changes in urination) Signs of gallbladder problems Additional Contraindications According to prescribing information, semaglutide should be used with caution or avoided in patients with history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy
(2010) 126:e1825
Hui H, Farilla L, Merkel P, Perfetti R (2002) The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects